iviral agents to augment our limited armamentarium of drugs available against SARS-CoV-2 to effectively combat COVID-19.
All the standard reference drugs used in the study like losartan, procainamide, cinacalcet, arbidol, hydroxychloroquine, oberadilol and poziotinib are FDA-approved drugs that were chosen for their specific